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Highlights (3 to 5 bullet points; maximum 85 characters, including spaces, per bullet 
point) 
 NAMPT inhibitor FK866 potentiated the effects of chemotherapeutic agent 
etoposide 
 FK866 and etoposide led to a strong induction of cell death in vitro 
 FK866 and etoposide acted via SIRT2 downregulation in p53 wildtype Molt-4 cells 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2 
Abstract 
NAMPT (Nicotinamide phosphoribosyltransferase) catalyses the rate-limiting step in the NAD 
biosynthesis from nicotinamide and thereby regulates the activity of NAD-dependent enzymes. 
Cancer cells are highly dependent on NAD for energy and DNA repair processes and are 
assumed to be more susceptible to an inhibition of NAD synthesis than non-transformed cells. 
We aimed to investigate whether or not inhibition of NAMPT with its specific inhibitor FK866 
can sensitize leukemia cells for chemotherapeutic agents. 
NAMPT protein abundance, enzymatic activity and NAD concentrations were significantly 
higher in Jurkat and Molt-4 leukemia cell lines compared to normal peripheral blood 
mononuclear cells. Combination of etoposide and FK866 caused increased cell death in 
leukemia cell lines compared to etoposide alone. Etoposide decreased protein abundance of 
NAD-dependent deacetylases SIRTUIN1. After combining etoposide and FK866 treatment 
SIRTUIN2 was further decreased and accumulation and acetylation of the downstream target 
p53 was further enhanced in MOLT4 cells. Concomitantly, protein abundance of p21 and 
cleaved BAX was increased. 
Targeting NAMPT could be a novel therapeutic strategy to enhance the efficacy of 
chemotherapeutic agents such as etoposide against leukemia. 
 
Keywords: NAMPT inhibition, NAD salvage, FK866, APO866, SIRT1, SIRT2, p53, p21, 
BAX, caspase, NMN, chemotherapy, apoptosis 
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Introduction 
Leukemia is the most common cancer diagnosed in children and represents approximately 30% 
of cancer diagnoses among children younger than 15 years (Belson et al., 2007). The main 
treatment for childhood leukemia is chemotherapy (Cooper and Brown, 2015). Children with 
high-risk leukemia or relapse generally receive more intense and aggressive chemotherapy, e.g. 
treatment with etoposide (Bhojwani et al., 2009; Locatelli et al., 2009).  Although  
chemotherapy is successful in up to 90% of pediatric patients with acute lymphoblastic 
leukemia, the toxicity of chemotherapy is a common cause of morbidity and mortality in 
children during treatment and later in life (Gervasini and Vagace, 2012). New strategies to 
reduce doses of chemotherapeutics are therefore urgently needed.  
Cancer cells are characterized by metabolic adaptations such as a high nicotinamide adenine 
dinucleotide (NAD) turnover rate due to increased proliferation, DNA repair and metabolism 
(Cea et al., 2013; Chiarugi et al., 2012). Nicotinamide phosphoribosyltransferase (NAMPT) is 
the key enzyme of the NAD salvage pathway from nicotinamide and thus a regulator of the 
intracellular NAD pool. NAMPT was shown to be overexpressed in different types of cancer, 
among them hematologic malignancies such as leukemia (Audrito et al., 2015) and lymphomas 
(Olesen et al., 2011). Given that, NAMPT may be crucial for maintaining cellular NAD levels 
in cancer cells to facilitate cancer proliferation and survival. It is therefore a potential 
therapeutic target for the treatment of cancer. 
SIRTUIN1 (SIRT1) and SIRT2 are NAD-dependent enzymes that are overexpressed in 
leukemia and could play a causal role in leukemia development (Dan et al., 2012; Kozako et 
al., 2012; Wang et al., 2011b). Furthermore, these two central SIRTs play an important role in 
tumor metabolism by deacetylating p53 and therefore regulating apoptosis (Luo et al., 2001; 
Peck et al., 2010).   
FK866 (APO866) is a specific inhibitor for NAMPT (Khan et al., 2006). Treatment with FK866 
reduced intracellular NAD levels leading to apoptosis and reduced cell proliferation in leukemia 
cell lines with functional tumor suppressor p53. This effect was mediated by increased 
acetylation of p53 at lysine 382 with subsequently increased expression of p21 and BAX. In 
contrast, leukemia cell lines containing nonfunctional p53 were relatively unaffected by FK866 
treatment (Thakur et al., 2013). Furthermore, FK866 had minor toxic effects on normal 
hematopoietic progenitor cells (Nahimana et al., 2009). Although FK866 was relatively well 
tolerated in humans and advanced to phase II clinical trials, it did not demonstrate sufficient 
tumor selectivity to achieve clinical success as single agent (von Heideman et al., 2010). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 4 
However, combining NAD depletion with chemotherapeutic agents might enhance their 
therapeutic efficacy (Thakur et al., 2013). In neuroblastoma cells, the effects of etoposide on 
DNA damage were potentiated by FK866 treatment, whereas the effect of FK866 on cytosolic 
NAD depletion was potentiated by etoposide (Travelli et al., 2011). In neuroendocrine tumors, 
the NAMPT inhibitor GMX1778 enhanced the efficacy of 177Lu-DOTATATE treatment and 
induced a prolonged antitumor response (Elf et al., 2016). 
The aim of this study is to test the hypothesis that NAMPT inhibition using the specific inhibitor 
FK866 makes leukemia cells more susceptible for chemotherapeutic agents and to elucidate 
underlying signalling pathways. 
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Materials&Methods 
Material 
Cell culture media and supplements were obtained from PAA (Cölbe, Germany) or Invitrogen 
(Karlsruhe, Germany). FK866 and nicotinamide mononucleotide (NMN) were obtained from 
Sigma Aldrich (Munich, Germany). Etoposide was purchased from Merck Millipore 
(Darmstadt, Germany). Primary antibodies were obtained from Cell Signaling (CST, Beverly, 
MA, USA) and Millipore. Secondary antibodies were purchased from DAKO (Hamburg, 
Germany). 
 
Cell culture 
Jurkat and Molt-4 T-ALL cell lines were purchased from Leibniz Institute DSMZ (German 
Collection of Microorganisms and Cell Cultures). The cell lines were cultured in RPMI 1640 
medium with 2 mmol/L glutamine and 10% fetal bovine serum (FBS) for Jurkat cells and 20% 
FBS for Molt-4 cells. All cells were grown at 37°C in a humidified atmosphere of 95% air and 
5% CO2. Cell number was measured using a hemacytometer after trypan blue staining. 
 
PBMC isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from anonymised blood buffy coats 
of healthy donors purchased from the University Hospital Leipzig Blood Bank. Buffy coats 
were diluted in lysis buffer (155mM NH4Cl; 10mM KHCO3; 0.1mM Na-EDTA; pH 7.29), 
gently mixed and kept on ice for 10 min. After centrifugation, the supernatant was removed 
carefully and the process was repeated until the pellet appeared clear.  
 
Cell treatments 
Etoposide was dissolved in DMSO to generate a stock solution of 42.5 mM. FK866 was 
dissolved in DMSO to create a stock solution of 10 mM. NMN was dissolved in the appropriate 
medium for a stock solution of 100 mM. Jurkat and Molt-4 cells were treated with the indicated 
concentrations of etoposide, indicated concentrations of FK866 or NMN [500μM] either alone 
or in combination for 24h. 
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Measurement of cell viability and cell death 
To investigate the effects of the chemotherapeutic agents on proliferation and cell viability, Cell 
Proliferation Reagent WST-1 (Roche, Grenzach-Wyhlen, Germany) was used according to 
manufacturer’s instructions. 40,000 cells/well were seeded in a 96-well plate and cultured as 
described above.  
To evaluate the effects of etoposide the number of dead cells was measured by flow cytometry 
using propidium iodide (PI) (Calbiochem, Dan Diego, CA, USA). 800,000 cells/well were 
seeded in a 6-well plate and cultured as described above. Cells were harvested and washed with 
ice-cold PBS. The cell pellet was re-suspended in 100μL of PBS with 0.5% FBS. Cell 
suspension was transferred into round bottom tubes. 2 μL of PI were added to the cell 
suspension, followed by gentle vortexing. Samples were incubated for 10 min on ice in darkness 
and analysed using a Beckton-Dickinson FACS LSRII. For each sample, 10,000 cells were 
counted. PI+ cells were considered dead. 
 
Protein extraction and Western blot analyses 
Cells were lysed in modified RIPA buffer as previously described (Schuster et al., 2014). 
Protein concentration was determined using Pierce BCA protein assay (Thermo Scientific) and 
equal amounts of protein were separated by SDS–PAGE and transferred to nitrocellulose 
membranes using a semi-dry transfer apparatus. Next, membranes were blocked in 5% non-fat 
dry milk in TBS buffer containing 0.1% Tween 20. Primary antibodies used for immunoblotting 
included anti-NAMPT (clone OMNI 379) (Cayman Chemical, Ann Arbor, MI, USA), anti-
Caspase-3, anti-PARP, anti-SIRT1, anti-SIRT2, anti-Ac-p53, anti-p53, anti-p21, anti-Bax (Cell 
Signaling, Beverly, MA, USA) and anti-GAPDH (Merck Millipore, Schwalbach, Germany). 
Appropriate secondary antibodies were purchased from DAKO (Hamburg, Germany). 
Detection of proteins was carried out using Luminata Classico Western HRP Substrate (Merck 
Millipore) or Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).  
 
NAMPT enzymatic activity 
NAMPT activity was measured by the conversion of 14C-labeled nicotinamide to 14C-NMN 
using a method previously described (Garten et al., 2010). Radioactivity of 14C-NMN was 
quantified in a liquid scintillation counter (Wallac 1409 DSA, PerkinElmer). 1 x 106 cells were 
seeded in dishes (152 cm²) and cultured as described above. NAMPT activity (counts per 
minute, cpm) was normalized to total protein concentration as measured by BCA protein assay. 
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NAD measurement 
Concentrations of total NAD from whole-cell extracts were quantified by HPLC analysis by 
reversed-phase HPLC using a Chromaster Purospher STAR RP-18 endcapped 3 µm Hibar RT 
150-3 HPLC column (Merck). 800,000 cells/well were seeded in a 6-well plate and cultured as 
described above. Cells were harvested and pellet was re-suspended in 100 µl 1 M perchloric 
acid. After a 10-minute incubation period on ice samples were centrifuged and the supernatant 
was neutralized with 3 M potassium carbonate. After repeated centrifugation samples were 
loaded onto the column as previously described (Schuster et al., 2014). 
The cell pellet of each sample was resuspended in 100 µl 2% SDS, shaken for 10 min at 99°C 
and centrifuged for 5 min at 20,000x g and then used for protein determination (BCA Assay, 
Pierce Thermo Scientific). The NAD concentration of each sample was referred to the 
corresponding total protein amount of the sample. 
 
Statistical analyses 
Data are presented as mean ± SEM. Data were analysed for statistical significance by either 
unpaired Student’s t-test or one-way analysis of variance (ANOVA) followed by Bonferroni 
post hoc test. All analyses were performed using GraphPad Prism 6 software (GraphPad 
Software, Inc., San Diego, CA, USA). ImageJ 1.41 was used for densitometric analysis (NIH, 
USA). p< 0.05 was considered significant compared to the referred control. 
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Results 
Cancer cell lines have higher NAMPT protein abundance and activity 
We compared the leukemia cell lines Jurkat (mutated p53) and Molt-4 (wildtype p53) (Cheng 
and Haas, 1990) with peripheral blood mononuclear cells (PBMCs) from healthy donors in 
regard to NAMPT protein abundance, NAMPT activity and  NAD levels. Jurkat and Molt-4 
cancer cell lines showed higher NAMPT protein abundance (25-fold in Jurkat cells, 21-fold in 
Molt-4 cells) compared to PBMCs (Fig. 1A). Furthermore, NAMPT activity (94.1 ± 18.2 
cpm/µg total protein x h in Jurkat cells; 24.6 ± 2.6 cpm/µg total protein x h in Molt-4 cells) 
(Fig. 1B) and NAD levels were elevated in cancer cell lines (9.5 ± 1.6 µmol NAD/g protein in 
Jurkat cells, 0.9 ± 0.2 µmol NAD/g protein in Molt-4 cells) compared to PBMCs (Fig. 1C). 
 
 
FK866 decreases viability, NAMPT activity and NAD levels 
We tested the sensitivity of Jurkat and Molt-4 cell lines to inhibition of NAMPT using the 
specific inhibitor FK866. Incubation of cells with FK866[10nM] for 24h reduced viability (-
59.5 ±3.3% in Jurkat cells, -46.1 ± 4.6% in Molt-4 cells) (Fig. 2A,B)(Supporting Information 
1 A,B). NAMPT activity was decreased in both cells lines significantly at a concentration of 1 
nM FK866 and was almost completely blocked after using a concentration of 10 nM FK866 in 
both cell lines. (Fig. 2 C,D). NAD concentrations were lowered (by 80% in Jurkat and Molt-4 
cells) (Fig. 2 E,F)(Supporting Information 1 C,D) compared to control cells. The enzymatic 
product of NAMPT, NMN [500µM], was able to rescue viability (Fig. 2A,B) and NAD levels 
(Fig. 2E,F) of both Jurkat and Molt-4 cells, whereas it had no effect alone. 
 
FK866 increases etoposide-induced cell death 
To evaluate whether NAMPT inhibition could enhance the effects of chemotherapeutic agents, 
Jurkat and Molt-4 cells were incubated with the anti-leukemia drugs etoposide (eto), 
methotrexate (mtx) and doxorubicin (doxo) alone or in combination with FK866 for 24h. 
Etoposide was able to induce cell death (4.0-fold ± 0.6 [10µM]) in Jurkat cells compared to 
control cells (Fig. 3A). Molt-4 cells were more sensitive to etoposide, which induced 5.6-fold 
± 1.0 [5µM] cell death (Fig. 3B). FK866 treatment alone did not induce cell death in both cell 
lines after 24h. However, the combination of etoposide and FK866 increased the number of 
dead cells compared to etoposide treatment alone (5.4-fold ± 1.4 in Jurkat cells, 1.8-fold ± 0.1 
in Molt-4 cells) (Fig. 3A,B). NMN was able to reverse the FK866-induced effects. Methotrexate 
(mtx) and doxorubicin (doxo) only induced cell death in Molt-4 cells (+17.8% ± 2.0% and 
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65.8% ± 8.2%, respectively). Combining mtx or doxo with FK866 did not increase cell death 
in Jurkat or Molt-4 cells (Supporting Information 2). 
Etoposide treatment induced cleavage and activation of caspase-3 and its downstream target 
poly (ADP-ribose) polymerase (PARP)-1, but this cleavage was not further increased by the 
addition of FK866 to etoposide (Fig. 3 C, D). A combination of etoposide and FK866 did not 
alter cell cycle distribution after 24h (Supporting Information 3). 
 
Etoposide-induced downregulation of SIRT2 is enhanced by NAD depletion  
Next, we aimed to determine whether the increased cell death provoked by etoposide and 
FK866 co-treatment could be caused by a further decrease in NAD levels. The NAD depletion 
induced by FK866 was not further enhanced by etoposide (Supporting Information 4). NAMPT 
protein abundance was not changed. However, etoposide treatment was able to decrease the 
amount of NAD-dependent deacetylases SIRT1 and SIRT2 dose-dependently in p53 wildtype 
Molt-4 cells. After etoposide treatment of NAD-depleted cells SIRT2 was even further 
decreased (Fig. 4A). The acetylation and activation of the SIRT1 as well as SIRT2 target p53 
was enhanced after co-treatment of etoposide with FK866, which was associated with an 
increased abundance of its downstream target p21 (Fig. 4B). Additionally, etoposide treatment 
induced cleavage of p53 downstream target BAX which was further enhanced by the 
combination with FK866. (Fig. 4B). Jurkat cells which harbour a mutated p53 did not show p53 
acetylation or altered levels of p21 or cleaved bax (Supporting Information 5). 
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Discussion 
Cancer cells have a high NAD turnover rate due to their increased proliferation, DNA repair, 
cell cycle progression and metabolism (Cea et al., 2013; Chiarugi et al., 2012). We therefore 
tested the efficacy of NAD depletion to sensitize leukemia cells for chemotherapeutic treatment 
with the aim to provide novel treatment options with reduced doses and consequently less 
adverse effects for patients. 
The NAD salvage enzyme NAMPT was shown to be overexpressed in hematologic 
malignancies (Audrito et al., 2015; Cagnetta et al., 2015; Olesen et al., 2011). We could confirm 
these findings and furthermore showed that basal NAMPT activity and NAD levels were also 
increased in leukemia cells in comparison to PBMCs from healthy volunteers.  
We used FK866 (APO866) to specifically target NAMPT (Khan et al., 2006). Thakur et al. 
proposed that leukemia cell lines containing nonfunctional p53 were relatively unaffected by 
FK866 (Thakur et al., 2013), whereas FK866 was able to induce cell death in p53-deficient 
hepatocarcinoma cells (Schuster et al., 2015). In our study, FK866 decreased viability, NAMPT 
activity and consequently depleted NAD levels in both p53 mutated (Jurkat) and p53 wildtype 
(Molt-4) cells.  
Given the influence of NAD depletion on regulators of cellular survival and stress responses, 
such as PARPs and sirtuins, we postulated that FK866 could synergize with chemotherapeutic 
agents that target the same pathways. Travelli et al. showed that the etoposide-specific effect 
of inducing DNA damage was potentiated by FK866 (Travelli et al., 2011). Contrary to their 
findings, however, we did not see an additive effect on total cellular NAD depletion (Supporting 
information 4). We could show that inhibition of NAMPT with FK866 in combination with 
etoposide led to increased cell death compared to etoposide alone. Interestingly, this effect was 
not mediated by the caspase cascade. This result stands in contrast to a study performed in 
HEK293 cells, where a knockdown of NAMPT made cells more sensitive to etoposide 
treatment and levels of cleaved caspase-3 were increased, whereas the overexpression of 
NAMPT led to a resistance of cells to etoposide and reduced levels of cleaved caspase 3 (Yang 
et al., 2007). However, apoptosis, autophagy as well as necrosis were proposed as mechanisms 
of cell death induction by FK866 (Cea et al., 2013; Gehrke et al., 2014; Nahimana et al., 2009) 
or combination treatments (Cagnetta et al., 2015; Nahimana et al., 2014; Travelli et al., 2011). 
The lack of apoptosis induction by FK866 could also be explained by the shorter treatment 
period we used compared to other studies (Schuster et al., 2015; Thakur et al., 2013). 
SIRT1 and SIRT2 are overexpressed in leukemia cells, both are involved in disease 
development and drug resistance (Deng et al., 2016; Li and Bhatia, 2015; Xu et al., 2015). In 
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our study, combining etoposide with FK866 decreased SIRT2 protein abundance in Molt-4 cells 
more than etoposide alone. Possible mechanisms leading to selective SIRT2 depletion could 
involve the up regulation of  microRNAs targeting SIRT2 (Li et al., 2016), as has been reported 
for the effects of etoposide on SIRT1 protein (Fan et al., 2014).  
P53 is a target of both SIRT1 and SIRT2 (Luo et al., 2001; Peck et al., 2010). Blocking SIRT1 
activity was shown to increase acetylation of p53 at lysine 382 in combination with DNA 
damaging agents (Audrito et al., 2011; Solomon et al., 2006). In the p53 wildtype cell line Molt-
4, we found an accumulation of p53 after treatment with etoposide (Golubovskaya and Cance, 
2013). Furthermore, the combined effect of FK866 and etoposide on SIRT2 was mirrored by 
an even stronger induction of p53 acetylation, higher expression of p53 downstream target p21 
and cleavage of BAX. The cleavage of BAX during apoptosis was shown to increase the 
intrinsic cytotoxic properties of this proapoptotic factor (Wood and Newcomb, 2000). This 
activation of p53-p21 signalling, as well as the increased cell death seen after co-treatment with 
etoposide and FK866, were reversible by supplementation with NMN, which confirmed the 
effects to be specific for NAD depletion (Espindola-Netto et al., 2017; LU et al., 2014; Yoshino 
et al., 2011). In Jurkat cells, which harbour a mutated p53, we did not detect p53 dependent 
changes in p21 or cleaved bax and no reduction in SIRT2 levels. A failure of p21 induction 
upon etoposide exposure has been shown before (Davies et al., 2011). Potentially, cell death in 
Jurkat cells could be induced via c-Myc. SIRT2 inhibits c-Myc ubiquitination and degradation 
supporting tumorigenesis. Vice versa, reduced SIRT2 activity due to NAD depletion leads to 
cell death by c-Myc ubiquitination and degradation (Jing et al., 2016). We therefore conclude 
that there are at least two pathways mediating the increased cell death seen upon combined 
treatment with etoposide and FK866 and that p53 is dispensable for cell death induction in this 
scenario. 
 
Conclusion 
Combined treatment with the NAMPT inhibitor FK866 potentiates the effects of 
chemotherapeutic agent etoposide and leads to a strong induction of cell death in vitro, via 
downregulation of SIRT2 and activation of the p53-p21 pathway in the p53 competent Molt-4 
cells. Targeting NAD salvage may be a useful strategy for chemo-sensitisation with the 
possibility to increase the efficacy of chemotherapeutic agents in the treatment of childhood 
leukemia. Additionally, SIRT2 inhibitors may represent interesting therapeutic options for p53 
wildtype leukemia. 
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Figure legends 
Fig. 1 NAMPT protein abundance, activity and NAD levels are higher in leukemia cell lines. 
NAMPT protein abundance (A), NAMPT activity (B) and NAD levels (C) were measured in PBMCs, Jurkat cells 
and Molt-4 cells. Western Blots show results of 3 independent experiments and lanes were analyzed 
densitometrically. Data are represented as mean ± SEM and statistical analysis was performed using one-way 
ANOVA and Bonferroni post hoc test (*p < 0.05 compared to PBMCs). 2-column fitting image 
 
Fig. 2 FK866 decreases viability, NAMPT activity and NAD levels. 
Viability (A,B), NAMPT activity (C,D) and NAD levels (E,F) were measured in Jurkat and Molt-4 cells after 
stimulation with FK866 with indicated concentrations and/or NMN [500µM] for 24h. Data are represented as 
mean ± SEM and statistical analysis was performed using unpaired Student’s t-test or one-way ANOVA with 
Bonferroni post hoc test (*p<0.05 compared to control; +p<0.05 compared to FK866). 2-column fitting image 
 
Fig. 3 FK866 increases etoposide-induced cell death. 
Jurkat and Molt-4 cells were stimulated with etoposide [0.1, 1, 5 or 10 µM] alone or in combination with FK866 
[10nM] and/or NMN [500µM] for 24h. Cell death was measured by flow cytometry using propidium iodide (A,B). 
Cleaved and full-lenght caspase-3 and PARP-1 protein abundance was detected by Western blot analysis (C,D). 
Western Blots show results of at least 3 independent experiments, GAPDH was used as loading control and lanes 
were analyzed densitometrically. Data are represented as mean ± SEM and statistical analysis was performed using 
one-way ANOVA and Bonferroni post hoc test (*p<0.05 compared to control; +p<0.05 compared to FK866 alone; 
#p<0.05 compared to etoposide [eto]; $ compared to eto+FK866). 2-column fitting image 
 
Fig. 4 Etoposide-induced downregulation of SIRT2 is enhanced by NAD depletion. 
Molt-4 cells were stimulated with etoposide [5 µM] alone or in combination with FK866 [10nM] and/or NMN 
[500µM] for 24h. NAMPT, SIRT1 and SIRT2 (A), acetyl-p53, p53, p21 and BAX (B) protein abundance was 
analysed by Western blot. Western Blots show results of at least 3 independent experiments and lanes were 
analyzed densitometrically. GAPDH was used as loading control. Data are represented as mean ± SEM and 
statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05 compared to 
control; +p<0.05 compared to FK866 alone; #p<0.05 compared to etoposide [eto]; $ compared to eto+FK866). 2-
column fitting image 
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